Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
NCT02854592 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000
Last updated 2019-12-17
Summary
Stroke is one of the leading causes of death and disability in China. Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within 4.5 hours of symptom onset. In China, in addition to rt-PA, intravenous urokinase within 6 h has also been recommended by the 2010 Chinese Guidelines for the Diagnosis and Treatment of Patients with Acute Ischemic Stroke, and supported by evidence from two intravenous urokinase thrombolysis trials. Urokinase is used more frequently than rt-PA, mainly because it is cheaper. To describe Chinese experience with thrombolytic therapy for Ischemic Stroke within 4.5h onset, we designed a multicenter, prospective, registry study. The aim of INtravenous Thrombolysis REgistry for Chinese Ischemic Stroke within 4.5 h onset(INTRECIS)was to assess the safety and efficacy of intravenous rtPA, urokinase as thrombolytic therapy within the first 4.5 h of onset of acute ischaemic stroke.
Conditions
Interventions
- DRUG
-
rtPA
intravenous thrombolysis with rtPa
- DRUG
-
urokinase
intravenous thrombolysis with urokinase
Sponsors & Collaborators
-
General Hospital of Shenyang Military Region
lead OTHER
Principal Investigators
-
Hui-Sheng Chen · General Hospital of Shenyang Military Region
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-01
- Primary Completion
- 2019-10-30
- Completion
- 2019-10-30
Countries
- China
Study Locations
More Related Trials
-
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
NCT05401149 ·Status: COMPLETED
-
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971 ·Status: RECRUITING ·Phase: PHASE3
-
Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China(IVTIS)
NCT06131385 ·Status: RECRUITING
-
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
NCT02930837 ·Status: COMPLETED ·Phase: PHASE3
-
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
NCT05752916 ·Status: COMPLETED ·Phase: PHASE4
-
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)
NCT05281549 ·Status: UNKNOWN ·Phase: PHASE2
-
Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke
NCT04733742 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
NCT03578822 ·Status: COMPLETED ·Phase: PHASE3
-
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
NCT04516993 ·Status: COMPLETED ·Phase: PHASE2
-
Endovascular Therapy for Acute Ischemic Stroke Trial
NCT02350283 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
NCT04624295 ·Status: RECRUITING ·Phase: PHASE4
-
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
NCT06194968 ·Status: RECRUITING
-
The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke
NCT02452502 ·Status: COMPLETED ·Phase: NA
-
Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK)
NCT04202458 ·Status: COMPLETED ·Phase: NA
-
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
NCT06551727 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism
NCT03284463 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months
NCT06841978 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
NCT06115070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
NCT04879615 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
NCT06211712 ·Status: RECRUITING ·Phase: NA
-
Argatroban Plus R-tPA for Acute Ischemic Stroke
NCT03740958 ·Status: COMPLETED ·Phase: PHASE4
-
Urokinase for Thrombolysis in Acute Ischemic Stroke
NCT07047326 ·Status: RECRUITING ·Phase: NA
-
Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke
NCT03552354 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke
NCT03686163 ·Status: COMPLETED ·Phase: PHASE4